Navigation Links
NovaBay Pharmaceuticals, Inc. Reports First Quarter 2009 Financial Results
Date:5/18/2009

Pharmaceuticals, Inc. Thomas J. Paulson, 510-899-8809 Chief Financial Officer tpaulson@novabaypharma.com Invigorate Communications Investor Relations: Gregory Gin, 908-376-7737 ggin@invigoratepr.com Media Relations: Mariesa Kemble, 608-850-4745 mkemble@invigoratepr.com 


                          NOVABAY PHARMACEUTICALS, INC
                    (formerly NovaCal Pharmaceuticals Inc.)
                        (a developmental stage company)

                           CONSOLIDATED BALANCE SHEETS
                      (in thousands, except per share data)


                                                    December 31, March 31,
                                                       2008        2009
                                                                (unaudited)
     ASSETS
        Current assets:
           Cash and cash equivalents                   $12,099  $10,243
           Short-term investments                            -    2,631
           Prepaid expenses and other current assets       414      684
           Total current assets                         12,513   13,558
        Property and equipment, net                      1,456    1,400
        TOTAL ASSETS                                   $13,969  $14,958

     LIABILITIES AND STOCKHOLDERS' EQUITY
     Liabilities:
        Current liabilities:
           Accounts payable                               $406     $367
           Accrued liabilities                           1,166    1,075
           Capital lease obligation                         42       39
           Equipment loan                                  366      376
           Deferred revenue                              2,500    3,836
           Total current liabil
'/>"/>
SOURCE  NovaBay Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8 9 

Related medicine news :

1. NovaBay Pharmaceuticals Scientific Advisor Receives American Chemical Societys Highest Award
2. NovaBay Pharmaceuticals Announces New Preclinical Data to be Presented at the American Academy of Dermatology (AAD) 67th Annual Meeting
3. NovaBay announces third quarter 2007 financial results
4. NovaBay Pharmaceuticals Closes Initial Public Offering of Common Stock
5. Keryx Biopharmaceuticals, Inc. Announces First Quarter 2009 Financial Results
6. Jiangbo Pharmaceuticals, Inc. Announces Conference Call to Discuss Results for its Third Quarter of FY 2009
7. Jiangbo Pharmaceuticals, Inc. to Present at CCG IRs China Rising Conference in New York
8. Jazz Pharmaceuticals, Inc. Announces First Quarter 2009 Financial Results
9. Genesis Pharmaceuticals Changes its Name to Jiangbo Pharmaceuticals, Inc. to Reflect its Brand Name
10. Lotus Pharmaceuticals, Inc. Reports Strong 2008 Financial Results
11. Alseres Pharmaceuticals, Inc. Receives Notice of De-Listing of Its Securities for Failure to Regain Compliance with Continued Listing Requirements
Post Your Comments:
*Name:
*Comment:
*Email:
Breaking Medicine News(10 mins):Health News:Regenerus Life Enhancement Programme from The Diagnostic Clinic Will Take the Fear Out of Ageing 2Health News:Regenerus Life Enhancement Programme from The Diagnostic Clinic Will Take the Fear Out of Ageing 3Health News:Regenerus Life Enhancement Programme from The Diagnostic Clinic Will Take the Fear Out of Ageing 4Health News:Regenerus Life Enhancement Programme from The Diagnostic Clinic Will Take the Fear Out of Ageing 5Health News:Regenerus Life Enhancement Programme from The Diagnostic Clinic Will Take the Fear Out of Ageing 6Health News:Wellness Manufacturer Wins Two 2009 American Spa Awards 2Health News:NVHR Offers Congressman Hank Johnson Support & Encouragement as He Battles Chronic Hepatitis C Virus 2Health News:Americans United for Life Action Fights the Abortion Bailout by Supporting the Nelson-Hatch-Casey Amendment 2Health News:Secure-24 and ATMP Consulting Group Launch Partnership for Private Practice Physicians to Meet IT and Electronic Medical Record Standards 2Health News:Secure-24 and ATMP Consulting Group Launch Partnership for Private Practice Physicians to Meet IT and Electronic Medical Record Standards 3
Breaking Medicine Technology:FDA Makes Interim Recommendations to Address Concern of Excess Radiation Exposure during CT Perfusion Imaging 2FDA Makes Interim Recommendations to Address Concern of Excess Radiation Exposure during CT Perfusion Imaging 3Royalty Pharma Announces that Alexander von Perfall Joins Management Team 2Q-Med AB and Oceana Therapeutics, Inc. Take Major Step Towards SOLESTA(TM) US Regulatory Filing 2Q-Med AB and Oceana Therapeutics, Inc. Take Major Step Towards SOLESTA(TM) US Regulatory Filing 3Baxa IntelliFlowRx 28TM 29 Upgrades Expand Pharmacy Capabilities 57968 1Baxa IntelliFlowRx 28TM 29 Upgrades Expand Pharmacy Capabilities 57968 2Baxa IntelliFlowRx 28TM 29 Upgrades Expand Pharmacy Capabilities 57968 3Oracle OpenWorld 2009 Panel to Feature Two Experts from National Healthcare Leadership Organizations the FDA and GS1 Healthcare US with Loftware 57966 1Oracle OpenWorld 2009 Panel to Feature Two Experts from National Healthcare Leadership Organizations the FDA and GS1 Healthcare US with Loftware 57966 2Oracle OpenWorld 2009 Panel to Feature Two Experts from National Healthcare Leadership Organizations the FDA and GS1 Healthcare US with Loftware 57966 3National Council on Disability to Recommend Health Care Changes for People With Disabilities 57964 1
Other Medicine Technology:Results of Two Phase 3 CAPACITY Studies of Pirfenidone in IPF Presented at American Thoracic Society (ATS) 2Results of Two Phase 3 CAPACITY Studies of Pirfenidone in IPF Presented at American Thoracic Society (ATS) 3Results of Two Phase 3 CAPACITY Studies of Pirfenidone in IPF Presented at American Thoracic Society (ATS) 4Results of Two Phase 3 CAPACITY Studies of Pirfenidone in IPF Presented at American Thoracic Society (ATS) 5Results of Two Phase 3 CAPACITY Studies of Pirfenidone in IPF Presented at American Thoracic Society (ATS) 6Results of Two Phase 3 CAPACITY Studies of Pirfenidone in IPF Presented at American Thoracic Society (ATS) 7Results of Two Phase 3 CAPACITY Studies of Pirfenidone in IPF Presented at American Thoracic Society (ATS) 8Results of Two Phase 3 CAPACITY Studies of Pirfenidone in IPF Presented at American Thoracic Society (ATS) 9Results of Two Phase 3 CAPACITY Studies of Pirfenidone in IPF Presented at American Thoracic Society (ATS) 10Results of Two Phase 3 CAPACITY Studies of Pirfenidone in IPF Presented at American Thoracic Society (ATS) 11Results of Two Phase 3 CAPACITY Studies of Pirfenidone in IPF Presented at American Thoracic Society (ATS) 12Terumo Heart, Inc. Reaches Clinical Milestone as the 100th Patient Worldwide Receives the DuraHeart(TM) Left Ventricular Assist System 2Terumo Heart, Inc. Reaches Clinical Milestone as the 100th Patient Worldwide Receives the DuraHeart(TM) Left Ventricular Assist System 3Terumo Heart, Inc. Reaches Clinical Milestone as the 100th Patient Worldwide Receives the DuraHeart(TM) Left Ventricular Assist System 4